355 related articles for article (PubMed ID: 11063179)
1. A review of inpatients with adverse drug reactions to allopurinol.
Khoo BP; Leow YH
Singapore Med J; 2000 Apr; 41(4):156-60. PubMed ID: 11063179
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Chohan S
J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?
Lee HY; Ariyasinghe JT; Thirumoorthy T
Singapore Med J; 2008 May; 49(5):384-7. PubMed ID: 18465047
[TBL] [Abstract][Full Text] [Related]
4. [Fatal liver necrosis due to allopurinol].
Pereira S; Almeida J; Silva AO; Quintas M; Candeias O; Freitas F
Acta Med Port; 1998 Dec; 11(12):1141-4. PubMed ID: 10192993
[TBL] [Abstract][Full Text] [Related]
5. Fatal allopurinol-induced hypersensitivity syndrome associated with pancreatic abnormalities.
Fathallah N; Ben Salem C; Slim R; Kaabia N; Letaief A; Bouraoui K
J Clin Rheumatol; 2010 Jun; 16(4):170-1. PubMed ID: 20511977
[TBL] [Abstract][Full Text] [Related]
6. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
Stamp LK; Taylor WJ; Jones PB; Dockerty JL; Drake J; Frampton C; Dalbeth N
Arthritis Rheum; 2012 Aug; 64(8):2529-36. PubMed ID: 22488501
[TBL] [Abstract][Full Text] [Related]
7. Allopurinol-induced drug reaction with eosinophilia and systemic symptoms syndrome with recurrence.
Yang DC; Chang CM
J Am Geriatr Soc; 2010 Oct; 58(10):2043-4. PubMed ID: 20929487
[No Abstract] [Full Text] [Related]
8. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
9. Allopurinol-induced DRESS syndrome.
Markel A
Isr Med Assoc J; 2005 Oct; 7(10):656-60. PubMed ID: 16259349
[TBL] [Abstract][Full Text] [Related]
10. [Side effects off allopurinol].
Rødevand E; Sletvold O; Kvande KT
Tidsskr Nor Laegeforen; 2004 Oct; 124(20):2618-9. PubMed ID: 15534635
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of desensitization to allopurinol following cutaneous reactions.
Fam AG; Dunne SM; Iazzetta J; Paton TW
Arthritis Rheum; 2001 Jan; 44(1):231-8. PubMed ID: 11212165
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse drug reactions in a hospital-based Chinese population.
Huang HY; Luo XQ; Chan LS; Cao ZH; Sun XF; Xu JH
Clin Exp Dermatol; 2011 Mar; 36(2):135-41. PubMed ID: 20738322
[TBL] [Abstract][Full Text] [Related]
13. Allopurinol induced generalized eosinophilic pustular folliculitis.
Ooi CG; Walker P; Sidhu SK; Gordon LA; Marshman G
Australas J Dermatol; 2006 Nov; 47(4):270-3. PubMed ID: 17034470
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events.
Dalbeth N; Stamp L
Semin Dial; 2007; 20(5):391-5. PubMed ID: 17897242
[TBL] [Abstract][Full Text] [Related]
15. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
17. Allopurinol-induced DRESS syndrome in an adolescent patient.
Dewan AK; Quinonez RA
Pediatr Dermatol; 2010; 27(3):270-3. PubMed ID: 19804493
[TBL] [Abstract][Full Text] [Related]
18. [Allopurinol-induced hypersensitivity syndrome].
Kinyó A; Lakatos A; Varga A; Gyulai R; Varga E; Bata-Csörgő Z; Kemény L
Orv Hetil; 2012 Apr; 153(15):586-91. PubMed ID: 22472359
[TBL] [Abstract][Full Text] [Related]
19. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
20. Frequency of serum creatinine monitoring during allopurinol therapy in ambulatory patients.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein AC; Gunter MJ; Lafata JE; Harrold L; Nelson WW; Platt R
Ann Pharmacother; 2006 Mar; 40(3):386-91. PubMed ID: 16478808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
